Subcutaneous administration of botulinum toxin a reduces formalin-induced pain

Pain

Volumn 107, Issue 1-2, 2004, Pages 125-133

  Cui, Minglei ^a   Khanijou, Sid ^a   Rubino, John ^a   Aoki, Kei Roger ^a  

^a ALLERGAN INC   (United States)

Author keywords

BOTOX ; Botulinum toxin A; Formalin model; Glutamate release; Inflammatory pain

Indexed keywords

BOTULINUM TOXIN A; FORMALDEHYDE; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG EFFECT; INFLAMMATION; MALE; MUSCLE WEAKNESS; NONHUMAN; PAIN; PRIORITY JOURNAL; PROVOCATION TEST; RAT;

EID: 0346094286     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2003.10.008     Document Type: Article

References (63)

1. Agrawal S.G., Evans R.H. The primary afferent depolarizing action of kainate in the rat. Br J Pharmacol. 87:1986;345-355.
2. Bill A., Stjernschantz J., Mandahl A., Brodin E., Nilsson G. Substance P: release on trigeminal nerve stimulation, effects in the eye. Acta Physiol Scand. 106:1979;371-373.
3. Binder W.J., Brin M.F., Blitzer A., Schoenrock L.D., Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 123:2000;669-676.
4. Brain S.D., Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol. 27:1996;607-611.
5. Brain S.D., Williams T.J., Tippins J.R., Morris H.R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 313:1985;54-56.
6. Brimijoin S., Lundberg J.M., Brodin E., Hokfelt T., Nilsson G. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig. Brain Res. 191:1980;443-457.
7. Brin M.F., Fahn S., Moskowitz C., Friedman A., Shale H.M., Greene P.E., Blitzer A., List T., Lange D., Lovelace R.E., McMahon D. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 2:1987;237-254.
8. Brin M.F., Swope D.M., O'Brien C., Abbasi S., Pogoda J.M. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalagia. 20:2000;421-422.
9. Brodin E., Gazelius B., Olgart L., Nilsson G. Tissue concentration and release of substance P-like immunoreactivity in the dental pulp. Acta Physiol Scand. 111:1981;141-149.
10. Cao Y.Q., Mantyh P.W., Carlson E.J., Gillespie A.M., Epstein C.J., Basbaum A.I. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 392:1998;390-394.
11. Carlton S.M., Coggeshall R.E. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res. 820:1999;63-70.
12. Carlton S.M., Honda C.N., Willcockson W.S., Lacrampe M., Zhang D., Denoroy L., Chung J.M., Willis W.D. Descending adrenergic input to the primate spinal cord and its possible role in modulation of spinothalamic cells. Brain Res. 543:1991;77-90.
13. Coderre T.J., Vaccarino A.L., Melzack R. Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. 535:1990;155-158.
14. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 52:1993;259-285.
15. Coggeshall R.E., Carlton S.M. Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery. J Comp Neurol. 391:1998;78-86.
16. Cui M., Khanijou S., Rubino J., Aoki K. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Soc Neurosci Abstr. (2000):2000;656.
17. Cui M., Li Z., You S., Khanijou S., Aoki K.R. Mechanism of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing. Naunyn Schmiedebergs Arch Pharmacol. 365:2002;365.
18. De Biasi S., Rustioni A. Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA. 85:1988;7820-7824.
19. Dickenson A.H., Sullivan A.F. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. Neurosci Lett. 83:1987;207-211.
20. Dolly J.O., Halliwell J.V., Black J.D., Williams R.S., Pelchen-Matthews A., Breeze A.L., Mehraban F., Othman I.B., Black A.R. Botulinum neurotoxin and dendrotoxin as probes for studies on transmitter release. J Physiol (Paris). 79:1984;280-303.
21. Du J., Koltzenburg M., Carlton S.M. Glutamate-induced excitation and sensitization of nociceptors in rat glabrous skin. Pain. 89:2001;187-198.
22. Du J., Zhou S., Coggeshall R.E., Carlton S.M. N-methyl-D-aspartate- induced excitation and sensitization of normal and inflamed nociceptors. Neuroscience. 118:2003;547-562.
23. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15:1992;96-103.
24. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
25. Duggan A.W., Hendry I.A. Laminar localization of the sites of release of immunoreactive substance P in the dorsal horn with antibody-coated microelectrodes. Neurosci Lett. 68:1986;134-140.
26. Evans R.H., Evans S.J., Pook P.C., Sunter D.C. A comparison of excitatory amino acid antagonists acting at primary afferent C fibres and motoneurones of the isolated spinal cord of the rat. Br J Pharmacol. 91:1987;531-537.
27. Freund B.J., Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 40:2000;231-236.
28. Go V.L., Yaksh T.L. Release of substance P from the cat spinal cord. J Physiol. 391:1987;141-167.
29. Gobel H., Heinze A., Heinze-Kuhn K., Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 91:2001;195-199.
30. deGroot J., Zhou S., Carlton S.M. Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. NeuroReport. 11:2000;497-502.
31. Haley J.E., Sullivan A.F., Dickenson A.H. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 518:1990;218-226.
32. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
33. Harmar A., Keen P. Synthesis, and central and peripheral axonal transport of substance P in a dorsal root ganglion-nerve preparation in vitro. Brain Res. 231:1982;379-385.
34. Heapy C.G., Jamieson A., Russel N.J.W. Afferent C-fiber and A-delta activity in models of inflammation. Br J Pharmacol. 90:1987;164B.
35. Hobson D.E., Gladish D.F. Botulinum toxin injection for cervicogenic headache. Headache. 37:1997;253-255.
36. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience. 24:1988;739-768.
37. Klemm F., Carli G., Reeh P.W. Peripheral neural correlates of the formalin test in the rat. Pflugers Arch. 414:1989;S42.
38. Kuraishi Y., Hirota N., Sato Y., Kaneko S., Satoh M., Takagi H. Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn. Brain Res. 359:1985;177-182.
39. Lembeck F., Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol. 310:1979;175-183.
40. Mahant N., Clouston P.D., Lorentz I.T. The current use of botulinum toxin. J Clin Neurosci. 7:2000;389-394.
41. Mochida S. Inhibition of neurotransmitter release by tetanus and botulinum neurotoxins. Seikagaku. 66:1994;254-259.
42. Montecucco C., Schiavo G., Tugnoli V., de Grandis D. Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today. 2:1996;418-424.
43. Omote K., Kawamata T., Kawamata M., Namiki A. Formalin-induced release of excitatory amino acids in the skin of the rat hindpaw. Brain Res. 787:1998;161-164.
44. Otsuka M., Konishi S. Release of substance P-like immunoreactivity from isolated spinal cord of newborn rat. Nature. 264:1976;83-84.
45. Poulain B., Tauc L., Maisey E.A., Wadsworth J.D., Mohan P.M., Dolly J.O. Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. Proc Natl Acad Sci USA. 85:1988;4090-4094.
46. Puig S., Sorkin L.S. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain. 64:1996;345-355.
47. Schulte-Mattler W.J., Wieser T., Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res. 4:1999;183-186.
48. Shone C.C., Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem. 207:1992;1009-1016.
49. Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2:2001;1649-1654.
50. Silberstein S., Mathew N., Saper J., Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 40:2000;445-450.
51. Svensson P., Cairns B.E., Wang K., Hu J.W., Graven-Nielsen T., Arendt-Nielsen L., Sessle B.J. Glutamate-evoked pain and mechanical allodynia in the human masseter muscle. Pain. 101:2003;221-227.
52. Taylor B.K., Peterson M.A., Basbaum A.I. Persistent cardiovascular and behavioral nociceptive responses to subcutaneous formalin require peripheral nerve input. J Neurosci. 15:1995;7575-7584.
53. Taylor B.K., Peterson M.A., Roderick R.E., Tate J., Green P.G., Levine J.O., Basbaum A.I. Opioid inhibition of formalin-induced changes in plasma extravasation and local blood flow in rats. Pain. 84:2000;263-270.
54. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., Hole K. The formalin test: an evaluation of the method. Pain. 51:1992;5-17.
55. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 38:2000;245-258.
56. Wheeler A.H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 38:1998;468-471.
57. Wheeler-Aceto H., Cowan A. Neurogenic and tissue-mediated components of formalin-induced edema: evidence for supraspinal regulation. Agents Actions. 34:1991;264-269.
58. Wheeler-Aceto H., Porreca F., Cowan A. The rat paw formalin test: comparison of noxious agents. Pain. 40:1990;229-238.
59. White D.M., Helme R.D. Release of substance P from peripheral nerve terminals following electrical stimulation of the sciatic nerve. Brain Res. 336:1985;27-31.
60. Willis W., Coggeshall R. Sensory mechanisms of the spinal cord. 1991;Plenum Press, New York.
61. Wonnacott S. Inhibition by botulinum toxin of acetylcholine release from synaptosomes: latency of action and the role of gangliosides. J Neurochem. 34:1980;1567-1573.
62. Yaksh T.L. Substance P release from knee joint afferent terminals: modulation by opioids. Brain Res. 458:1988;319-324.
63. Zhou S., Bonasera L., Carlton S.M. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. NeuroReport. 7:1996;895-900.